Citations

Showing 10 of 107868 citations.

Inverse estimation of viscoelastic material properties for solids immersed in fluids using vibroacoustic techniques
Brigham, John C. , Aquino, Wilkins , Mitri, F.G. , Greenleaf, James F. , Fatemi, Mostafa , Fatemi, Mostafa

Mayo Clinic

Journal of Applied Physics | January 18, 2007 | Volume: 101 | Issue: 2 | Pages: No page available

10.1063/1.2423227 Get It

This work presents an approach to inversely determine material properties for solids immersed in fluids through the use of steady-state dynamic response. The methodology uses measured acoustic pressure amplitudes in the fluid surrounding a structure being vibrated with a harmonic force to determine the parameters for elastic and viscoelastic material models. Steady-state dynamic finite element analysis is used to compute the frequency response function of homogeneous and heterogeneous solids. The frequency response is then used to inversely estimate material parameters. In order to solve the inverse problem, an optimization method is presented which combines the global search capabilities of the random search method with the reduced computational time of a surrogate model approach. Through numerical and laboratory experiments, this work shows that acoustic emissions hold sufficient information for quantifying both elastic and viscoelastic material behaviors. Furthermore, the examples show that the surrogate model accelerated random search algorithm is an efficient and accurate method for solving these types of inverse problems. This research has direct and important implications in nondestructive evaluation of material properties in general. However, the examples shown in this paper are based on applications related to noninvasive characterization of biological materials through methodologies currently applied to medical imaging.
Subfascial endoscopic perforator vein surgery: indications and results
Gloviczki, Péter , Gloviczki, Péter

Mayo Clinic

Vascular Medicine | January 18, 2007 | Volume: 4 | Issue: 3 | Pages: 173-180

10.1177/1358836x9900400308 | PMID 10512597 Get It

Subfascial endoscopic perforator surgery (SEPS) is a new, minimally invasive technique performed in patients with advanced chronic venous insufficiency. The objective of the operation is to interrupt incompetent medial calf perforating veins to decrease venous reflux and reduce ambulatory venous hypertension in critical areas above the ankle where venous ulcers most frequently develop. Patients with stasis skin changes and healed or active venous ulcerations are potential candidates for the operation. Preoperative evaluation is performed with duplex scanning of the superficial, deep and perforator system, to diagnose both obstruction and valvular incompetence. Results of the North American SEPS Registry (NASEPS) as well as experience in several individual centers confirmed that the operation has significantly fewer wound complications than the classic open surgical techniques, and that rapid ulcer healing can be achieved. At the Mayo Clinic an ulcer recurrence rate of 12% was observed, with recurrence significantly more frequent in post-thrombotic limbs than in patients with primary venous valvular incompetence. The NASEPS Registry report confirmed a 2-year cumulative ulcer recurrence rate of 28%; ulcer recurrence was significantly more frequent in post-thrombotic limbs, especially in those with deep venous obstruction. SEPS is a new, low-risk, outpatient procedure that effectively decreases perforator reflux in patients with venous ulcerations, and should be added to our armamentarium to treat patients with advanced chronic venous disease. Long-term prospective and randomized studies are, however, still required to provide level I evidence of late efficacy.
Editorial opinion piece
Rooke, Thom W.

Mayo Clinic

Vascular Medicine | January 18, 2007 | Volume: 6 | Issue: 4 | Pages: 271-272

10.1177/1358836x0100600414 | PMID 11958397 Get It

Images in vascular medicine
Tse, Tak-Sun, Cooper, Leslie T.

Mayo Clinic

Vascular Medicine | January 18, 2007 | Volume: 6 | Issue: 4 | Pages: 267-268

10.1177/1358836x0100600412 | PMID 11958395 Get It

Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication
Cooper, Leslie T. , Hiatt, William R. , Regensteiner, Judith G. , Casscells, Ward, Isner, Jeffrey M., Hirsch, Alan T., Creager, Mark A. , Cooke, John P. , Cooper, Leslie T

Mayo Clinic

Vascular Medicine | January 18, 2007 | Volume: 6 | Issue: 4 | Pages: 235-239

10.1177/1358836x0100600406 | PMID 11958389 Get It

Intermittent claudication is the most common symptom of peripheral arterial disease (PAD), in part due to an inadequate rise in limb blood flow with exercise. Claudication causes a severe impairment in functional capacity and quality of life in over 3 million Americans. Basic fibroblast growth factor (bFGF) stimulates angiogenesis in vivo and improves limb blood flow in several animal models of hindlimb ischemia. However, the relative safety and efficacy of angiogenic molecules in the treatment of claudication has not been fully evaluated in prospective, blinded clinical trials. In this study, a randomized, double-blind, placebo-controlled, phase II trial of recombinant human bFGF for the treatment of intermittent claudication was performed. bFGF was administered weekly by intravenous infusions of 2 μg/kg for 6 sequential weeks (total dose 12 μg/kg). The primary efficacy endpoint was change in peak walking time (PWT) on a graded exercise treadmill protocol. Secondary efficacy endpoints included changes in functional status as measured by validated questionnaires. The study was stopped prematurely after treatment of the first 24 subjects due to proteinuria in five of the 16 subjects who received systemic bFGF, which exceeded 1000 mg/24 h in four of these five subjects. The small sample size limited evaluation of the predefined efficacy endpoints; however, there was no significant difference between the treatment and control groups for any of the measures of efficacy. In conclusion, intravenous administration of bFGF delivered at low doses weekly for 6 weeks was associated with a high rate of severe proteinuria. It is speculated that bFGF-related proteinuria in this study was primarily related to the systemic route of administration and the frequent dosing schedule. Future clinical trials of bFGF protein should carefully monitor renal function and consider alternative dosing schedules and drug administration routes.
Short-term treatment with transdermal nicotine affects the function of canine saphenous veins
Rud, Kevin S., Hurt, R. Douglas , Miller, Virginia M. , Clouse, William Darrin

Mayo Clinic

Vascular Medicine | January 18, 2007 | Volume: 5 | Issue: 2 | Pages: 75-82

10.1177/1358836x0000500203 | PMID 10943583 Get It

Experiments were designed to determine the effects of nicotine treatment on the functions of saphenous veins used for coronary artery bypass grafts in dogs. Dogs received either no treatment or transdermal nicotine for 5 weeks at doses of 11 mg, 22 mg or 44 mg/day. Saphenous veins were removed and suspended for the measurement of isometric force in organ chambers. Endothelium was removed mechanically from some rings. N G -mono-methyl-l-arginine (l-NMMA; 10 - 4 M) was used to inhibit the production of nitric oxide. Contractions to alpha 2 -adrenergic stimulation were decreased in veins from dogs treated with a 22-mg/day dose of transdermal nicotine. In addition, endothelium-dependent relaxations to adenosinediphosphate (10 - 8 -10 - 4 M) and the calcium ionophore A23,187 (10 - 8 -10 - 6 M) were decreased in veins from dogs with a 22-mg/day dose and increased in veins from dogs treated with a 44-mg/day dose. These relaxations were inhibited by l-NMMA. Plasma concentrations of oxidized products of nitric oxide were decreased only in dogs treated with 22 mg/day of nicotine. The relaxation of rings without endothelium (direct response on the smooth muscle) to nitric oxide were not altered by nicotine treatment. These results suggest that the short-term treatment of dogs with intermediate (22 mg/day) but not low (11 mg/day) or high (44 mg/day) doses of transdermal nicotine decreases the endothelial function of veins used for coronary artery bypass grafts. Therefore, changes in plasma products of nitric oxide and endothelium-depen-dent relaxations mediated by nitric oxide are related to the dose of nicotine treatment.
Circulator boot therapy alters the natural history of ischemic limb ulceration
Carlson, Lori A, Blier, Bill, Felty, Cindy L., Kuiper, James D., Rooke, Thom W. , Vella, Adrian

Mayo Clinic

Vascular Medicine | January 18, 2007 | Volume: 5 | Issue: 1 | Pages: 21-25

10.1177/1358836x0000500104 | PMID 10737152 Get It

Despite numerous advances in interventional radiology and vascular surgery, the clinician continues to be confronted with inoperable vascular disease. Previous studies have shown that ulceration associated with a transcutaneous oxygen pressure (tcPO 2 )of,20 mmHg is refractory to all attempts at healing. External pneumatic compression for the treatment of peripheral vascular disease has been available for several years, although there is a relative paucity of data regarding its role in clinical practice as well as its efficacy. The objective of this study was to examine the experience with circulator boot therapy in the treatment of ischemic ulcers in the absence of osteomyelitis, and specifically to determine whether such therapy can be of benefit in ischemic limb ulceration associated with a tcPO 2 of,20 mmHg. A retrospective chart review was undertaken of all patients with a lower limb ulcer who, in the absence of osteomyelitis, underwent circulator boot therapy at the Gonda Vascular Center. A total of 98 patients was identified. Two patients died within 1 month of commencing therapy and were not included in further analysis. The tcPO 2 data were unavailable in five patients. Outcome in the patient population was classified as favorable if (1) healing was achieved, (2) the ulcer decreased in size, or (3) the affected limb improved sufficiently to allow successful revascularization. An unfavorable outcome was one where a major amputation was performed or where the ulcer increased in size. Out of a total of 29 patients with a tcPO 2 ,20 mmHg at the area of ulceration, 19 had a favorable outcome following circulator boot therapy. Of the remaining 62 patients with a tcPO 2 .20 mmHg, 54 had a favorable outcome. Circulator boot therapy is associated with improved outcomes in limb ulceration due to peripheral vascular disease. Complete ulcer healing as well as preservation of the affected limb can be achieved in most cases.
Databases in MS research: pitfalls and promises
Weinshenker, Brian G.

Mayo Clinic

Multiple Sclerosis Journal | January 18, 2007 | Volume: 5 | Issue: 4 | Pages: 206-211

10.1177/135245859900500402 | PMID 10467376 Get It

A database is an organized repository of data. Prospective collection of patient information in a database (`databasing') has been attempted by a few consortia of MS investigators over the past 10 years. This approach promises to facilitate epidemiologic research in MS and investigation of the natural history of the disease and how it might be altered by long-term treatments such as interferon beta. Databasing has some advantages over clinical trials in assessing new therapies, primarily because the focus is on long-term effectiveness in an entire population rather than short-term statistical significance in a highly selected population. The limitations of databasing and strategies to overcome these limitations are addressed.
A unique population of circulating autoantibodies promotes central nervous system remyelination
Asakura, K., Rodriguez, Moses

Mayo Clinic

Multiple Sclerosis Journal | January 18, 2007 | Volume: 4 | Issue: 3 | Pages: 217-221

10.1177/135245859800400324 | PMID 9762677 Get It

In previous studies we demonstrated that the humoral immune response directed against unique central nervous system (CNS) antigens enhanced CNS remyelination in the Theiler's virus experimental model of multiple sclerosis (MS). To expand on this observation, a mouse IgMk monoclonal antibody (mAb) which enhances CNS remyelination, was raised against normal mouse spinal cord homogenate. Characterization of this mAb revealed that it is polyreactive towards variety of intracellular antigens but also reacts to an unidentified surface antigen on oligodendrocytes. The mAb is encoded by germline immunoglobulin genes without somatic mutations consistent with the observation that it is a natural autoantibody. Recently we generated another mouse IgMk mAb raised against normal spinal cord homogenate, which also promotes CNS remyelination. Further characterization revealed that both mAbs which promote remyelination have similar binding characteristics. Conventionally Abs which recognize normal CNS components, especially oligodendrocytes or myelin, have been considered to be a disease marker or be involved in the pathogenesis of MS. However, we have identified a unique population of circulating autoantibodies which are beneficial for myelin repair. Therefore this observation indicates the need to reevaluate autoantibody production against myelin components in CSF and blood as markers of disease activity versus repair in MS.
Update on the International Project on Pathologic Correlates in MS
Lucchinetti, Claudia F.

Mayo Clinic

Multiple Sclerosis Journal | January 18, 2007 | Volume: 11 | Issue: 1 | Pages: 99-100

10.1177/135245850501100120 | PMID 15732277 Get It